Long-term results in patients with Lyme arthritis following treatment with ceftriaxone
Language English Country Germany Media print
Document type Journal Article
PubMed
8852482
DOI
10.1007/bf01780670
Knihovny.cz E-resources
- MeSH
- Borrelia burgdorferi Group immunology isolation & purification MeSH
- Time Factors MeSH
- Ceftriaxone therapeutic use MeSH
- Adult MeSH
- Arthritis, Infectious complications drug therapy immunology pathology MeSH
- Middle Aged MeSH
- Humans MeSH
- Lyme Disease complications drug therapy immunology pathology MeSH
- Follow-Up Studies MeSH
- Antibodies, Bacterial blood MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Consumer Product Safety MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Ceftriaxone MeSH
- Antibodies, Bacterial MeSH
A total of 35 patients with late stage Lyme borreliosis with involvement of the joints was followed up until 3 years after a 14 day course of 2 g ceftriaxone once daily i.v. Diagnosis was confirmed by indirect and direct microbiological methods as well as clinical signs and symptoms. Long term clinical results in 26 patients at 36 months were complete response or marked improvement in 19, relapse in six and new manifestations in four of the cases, respectively. Possible mechanisms for non-responding to therapy are discussed. Therapy was well tolerated; in no case discontinuation of treatment was necessary due to adverse drug reactions. The treatment results in this group of 35 patients with Lyme arthritis are considered successful. The data obtained are consistent with expectations based on the published experiences with ceftriaxone in this indication.
See more in PubMed
Ann Rheum Dis. 1992 Aug;51(8):1007-8 PubMed
Cent Eur J Public Health. 1993 Dec;1(2):81-5 PubMed
Lancet. 1991 Jul 20;338(8760):193 PubMed
J Infect Dis. 1988 Oct;158(4):905-6 PubMed
N Engl J Med. 1990 Jul 26;323(4):219-23 PubMed
Drugs. 1992 May;43(5):683-99 PubMed
Arthritis Rheum. 1993 Nov;36(11):1621-6 PubMed
Klin Wochenschr. 1986 Mar 3;64(5):206-15 PubMed
Arch Intern Med. 1990 Aug;150(8):1677-82 PubMed
Arthritis Rheum. 1977 Jan-Feb;20(1):7-17 PubMed
J Basic Microbiol. 1989;29(2):73-83 PubMed
Lancet. 1988 May 28;1(8596):1191-4 PubMed
N Engl J Med. 1994 Jan 27;330(4):229-34 PubMed
Am J Med. 1994 Apr;96(4):365-74 PubMed
J Rheumatol. 1989 Nov;16(11):1502-5 PubMed
Ann Intern Med. 1991 Mar 15;114(6):472-81 PubMed
J Am Acad Dermatol. 1993 Feb;28(2 Pt 2):312-4 PubMed
Am J Med. 1992 Apr;92(4):396-403 PubMed
J Infect Dis. 1993 May;167(5):1074-81 PubMed
Arthritis Rheum. 1989 Sep;32(9):1057-64 PubMed
Infect Immun. 1993 Jul;61(7):2774-9 PubMed
